Oragenics Files 8-K: Other Events & Financials
Ticker: OGEN · Form: 8-K · Filed: May 7, 2024 · CIK: 1174940
Sentiment: neutral
Topics: 8-K, financials, regulatory-filing
TL;DR
Oragenics dropped an 8-K on 5/7 - check it for new events and financials.
AI Summary
Oragenics, Inc. filed an 8-K on May 7, 2024, reporting other events and financial statements/exhibits. The company, incorporated in Florida with its principal executive offices in Sarasota, FL, operates in the pharmaceutical preparations industry.
Why It Matters
This filing provides updates on significant company events and financial disclosures, which are crucial for investors to assess the company's current status and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting standard events and exhibits, not indicating any immediate or significant new risks.
Key Numbers
- 001-32188 — SEC File Number (Identifies the company's filing history with the SEC.)
- 59-3410522 — IRS Employer Identification Number (Tax identification number for the company.)
Key Players & Entities
- Oragenics, Inc. (company) — Registrant
- May 7, 2024 (date) — Date of earliest event reported
- Sarasota, FL (location) — Principal executive offices
- 1990 Main Street Suite 750 (address) — Business Address
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text does not detail the specific 'Other Events' but indicates that this section is included in the filing.
What is the primary business of Oragenics, Inc. according to the filing?
Oragenics, Inc. is in the 'Pharmaceutical Preparations' industry, SIC code 2834.
When was the earliest event reported in this Form 8-K?
The earliest event reported was on May 7, 2024.
Where are Oragenics, Inc.'s principal executive offices located?
The principal executive offices are located at 1990 Main Street Suite 750, Sarasota, FL 34236.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Stats: 419 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2024-05-07 08:14:33
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex99-1.htm (EX-99.1) — 12KB
- 0001493152-24-018025.txt ( ) — 227KB
- ogen-20240507.xsd (EX-101.SCH) — 3KB
- ogen-20240507_lab.xml (EX-101.LAB) — 33KB
- ogen-20240507_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this May 7, 2024. ORAGENICS, INC. (Registrant) BY: /s/ Janet Huffman Janet Huffman Chief Financial Officer